

Supplementary Table 1. Baseline characteristics of reports on vaccineassociated ischemic stroke adverse events

| Variables         Value (n=5,843)           Region reporting         African Region         10 (0.17)           Region of the Americas         2,976 (50.93)           South-East Asia Region         37 (0.63)           European Region         2,663 (45.58)           Eastern Mediterranean Region         52 (0.89)           Western Pacific Region         105 (1.80)           Reporting year         2010–2019         41 (0.70)           2020–2023         5,802 (99.30)           Reporter qualification         Health Professional         1,627 (27.85)           Non-Health Professional         4,216 (72.15)           Studies         Study-related         30 (0.51)           Sex         Male         2,947 (50.44)           Female         2,851 (48.79)           Unknown         45 (0.77)           Age, years         18-44         500 (8.56)           45-64         1,469 (25.14)           65-74         1,054 (18.04)           ≥75         1,432 (24.51)           Unknown         1,388 (23.75)           Delay (TTO), days         Median (01–03)         1 (1–1)           Drug class         Influenza vaccines         61 (1.04)           COVID-19 mRNA vaccines         4,  |   | ,               |
|--|---|-----------------|
| African Region 10 (0.17) Region of the Americas 2,976 (50.93) South-East Asia Region 37 (0.63) European Region 2,663 (45.58) Eastern Mediterranean Region 52 (0.89) Western Pacific Region 105 (1.80) Reporting year 2010-2019 41 (0.70) 2020-2023 5,802 (99.30) Reporter qualification Health Professional 1,627 (27.85) Non-Health Professional 4,216 (72.15) Studies Study-related 5,813 (99.49) Non-study related 30 (0.51) Sex Male 2,947 (50.44) Female 2,851 (48.79) Unknown 45 (0.77) Age, years 18-44 500 (8.56) 45-64 1,469 (25.14) 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75) Delay (TTO), days Median (01-03) 1 (1-1) Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID-19 vaccines 55 (0.94) Others* 42 (0.72) Fatal Utcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)   | Variables                                 | Value (n=5,843) |
| Region of the Americas  South-East Asia Region  European Region  European Region  Eastern Mediterranean Region  Western Pacific Region  Reporting year  2010-2019  41 (0.70)  2020-2023  Reporter qualification  Health Professional  Non-Health Professional  Non-Health Professional  Non-study related  Sex  Male  2,947 (50.44)  Female  2,851 (48.79)  Unknown  45 (0.77)  Age, years  18-44  45-64  45-64  45-64  45-64  45-64  45-64  45-64  45-64  45-64  1,054 (18.04)  ≥75  1,432 (24.51)  Unknown  1,388 (23.75)  Delay (ITO), days  Median (Q1-Q3)  1 (1-1)  Drug class  Influenza vaccines  61 (1.04)  COVID-19 mRNA vaccines  AdS-vectored COVID-19 vaccines  Alive  2,905 (49.72)  Fatal  Unknown  2,694 (46.11)  | Region reporting                          |                 |
| South-East Asia Region 37 (0.63) European Region 2,663 (45.58) Eastern Mediterranean Region 52 (0.89) Western Pacific Region 105 (1.80) Reporting year 2010-2019 41 (0.70) 2020-2023 5,802 (99.30) Reporter qualification Health Professional 1,627 (27.85) Non-Health Professional 4,216 (72.15) Studies Study-related 5,813 (99.49) Non-study related 30 (0.51) Sex Male 2,947 (50.44) Female 2,851 (48.79) Unknown 45 (0.77) Age, years 18-44 500 (8.56) 45-64 1,469 (25.14) 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75) Delay (ITO), days Median (Q1-Q3) 1 (1-1) Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72) Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)  | African Region                            | 10 (0.17)       |
| European Region 2,663 (45.58)  Eastern Mediterranean Region 52 (0.89)  Western Pacific Region 105 (1.80)  Reporting year  2010-2019 41 (0.70)  2020-2023 5,802 (99.30)  Reporter qualification  Health Professional 1,627 (27.85)  Non-Health Professional 4,216 (72.15)  Studies  Study-related 5,813 (99.49)  Non-study related 30 (0.51)  Sex  Male 2,947 (50.44)  Female 2,851 (48.79)  Unknown 45 (0.77)  Age, years  18-44 500 (8.56)  45-64 1,469 (25.14)  65-74 1,054 (18.04)  ≥75 1,432 (24.51)  Unknown 1,388 (23.75)  Delay (TTO), days  Median (01-03) 1 (1-1)  Drug class  Influenza vaccines 61 (1.04)  COVID-19 mRNA vaccines 4,587 (78.50)  Ad5-vectored COVID-19 vaccines 55 (0.94)  Others* 42 (0.72)  Fatal outcomes  Alive 2,905 (49.72)  Fatal Unknown 2,694 (46.11)  | Region of the Americas                    | 2,976 (50.93)   |
| Eastern Mediterranean Region Western Pacific Region 105 (1.80)  Reporting year 2010–2019 2020–2023 5,802 (99.30)  Reporter qualification Health Professional Health Professional Non-Health Professional Non-study related Non-study related Non-study related 1,627 (27.85) Non-Health Professional Non-study related 30 (0.51)  Sex  Male 2,947 (50.44) Female 2,851 (48.79) Unknown 45 (0.77)  Age, years 18-44 500 (8.56) 45-64 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (ITO), days Median (01-03) 1 (1-1)  Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)   | South-East Asia Region                    | 37 (0.63)       |
| Western Pacific Region       105 (1.80)         Reporting year       2010–2019       41 (0.70)         2020–2023       5,802 (99.30)         Reporter qualification       Health Professional       1,627 (27.85)         Non-Health Professional       4,216 (72.15)         Studies       Study-related       5,813 (99.49)         Non-study related       30 (0.51)         Sex       Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (ITO), days         Median (01–03)       1 (1–1)         Drug class       1nfluenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes         Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | European Region                           | 2,663 (45.58)   |
| Reporting year 2010–2019   | Eastern Mediterranean Region              | 52 (0.89)       |
| 2010–2019 2020–2023 5,802 (99.30)  Reporter qualification Health Professional Non-Health Professional Non-Health Professional Study-related Study-related Non-study related Sound (0.51)  Sex Male Female Study-related Sound (0.51)  Sex Male Female Sound (0.50) Unknown Sound (0.50)  Age, years  18–44 Sound (0.50) 45–64 Sound (0.50) Sound (18.04) Found (19.04) Found (19.05) Found (19.06) Found (19.07) Found | Western Pacific Region                    | 105 (1.80)      |
| 5,802 (99.30)         Reporter qualification         Health Professional       1,627 (27.85)         Non-Health Professional       4,216 (72.15)         Studies         Study-related       5,813 (99.49)         Non-study related       30 (0.51)         Sex         Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years         18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (ITO), days       Median (01-03)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | Reporting year                            |                 |
| Reporter qualification  Health Professional 1,627 (27.85)  Non-Health Professional 4,216 (72.15)  Studies  Study-related 5,813 (99.49)  Non-study related 30 (0.51)  Sex  Male 2,947 (50.44)  Female 2,851 (48.79)  Unknown 45 (0.77)  Age, years  18-44 500 (8.56)  45-64 1,469 (25.14)  65-74 1,054 (18.04)  ≥75 1,432 (24.51)  Unknown 1,388 (23.75)  Delay (ITO), days  Median (Q1-Q3) 1 (1-1)  Drug class  Influenza vaccines 61 (1.04)  COVID-19 mRNA vaccines 4,587 (78.50)  Ad5-vectored COVID-19 vaccines 1,098 (18.79)  Inactivated whole-virus COVID-19 vaccines 55 (0.94)  Others* 42 (0.72)  Fatal outcomes  Alive 2,905 (49.72)  Fatal 244 (4.18)  Unknown 2,694 (46.11)   | 2010–2019                                 | 41 (0.70)       |
| Health Professional  Non-Health Professional  Non-Health Professional  Studies  Study-related  Non-study related  S,813 (99.49)  Non-study related  30 (0.51)  Sex  Male  2,947 (50.44)  Female  2,851 (48.79)  Unknown  45 (0.77)  Age, years  18-44  500 (8.56)  45-64  65-74  1,054 (18.04)  ≥75  1,432 (24.51)  Unknown  1,388 (23.75)  Delay (TTO), days  Median (Q1-Q3)  1 (1-1)  Drug class  Influenza vaccines  61 (1.04)  COVID-19 mRNA vaccines  4,587 (78.50)  Ad5-vectored COVID-19 vaccines  1,098 (18.79)  Inactivated whole-virus COVID-19 vaccines  55 (0.94)  Others*  42 (0.72)  Fatal outcomes  Alive  2,905 (49.72)  Fatal  Unknown  2,694 (46.11)   | 2020–2023                                 | 5,802 (99.30)   |
| Non-Health Professional 4,216 (72.15)  Studies  Study-related 5,813 (99.49)  Non-study related 30 (0.51)  Sex  Male 2,947 (50.44)  Female 2,851 (48.79)  Unknown 45 (0.77)  Age, years  18-44 500 (8.56)  45-64 1,469 (25.14)  65-74 1,054 (18.04)  ≥75 1,432 (24.51)  Unknown 1,388 (23.75)  Delay (TTO), days  Median (Q1-Q3) 1 (1-1)  Drug class  Influenza vaccines 61 (1.04)  COVID-19 mRNA vaccines 4,587 (78.50)  Ad5-vectored COVID-19 vaccines 1,098 (18.79)  Inactivated whole-virus COVID-19 vaccines 55 (0.94)  Others* 42 (0.72)  Fatal outcomes  Alive 2,905 (49.72)  Fatal 244 (4.18)  Unknown 2,694 (46.11)  | Reporter qualification                    |                 |
| Studies       5,813 (99.49)         Non-study related       30 (0.51)         Sex       Male         Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       18-44         18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days         Median (Q1-Q3)       1 (1-1)         Drug class       Influenza vaccines         Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes         Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | Health Professional                       | 1,627 (27.85)   |
| Studies       5,813 (99.49)         Non-study related       30 (0.51)         Sex       Male         Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       18-44         18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days         Median (Q1-Q3)       1 (1-1)         Drug class       Influenza vaccines         Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes         Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | Non-Health Professional                   | 4,216 (72.15)   |
| Non-study related       30 (0.51)         Sex       Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days       Median (Q1-Q3)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | Studies                                   |                 |
| Non-study related       30 (0.51)         Sex       Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       18-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days       Median (Q1-Q3)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   | Study-related                             | 5,813 (99.49)   |
| Sex       Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       8-44       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days       Median (Ω1-Q3)         Median (Ω1-Q3)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   |                 |
| Male       2,947 (50.44)         Female       2,851 (48.79)         Unknown       45 (0.77)         Age, years       500 (8.56)         45-64       1,469 (25.14)         65-74       1,054 (18.04)         ≥75       1,432 (24.51)         Unknown       1,388 (23.75)         Delay (TTO), days         Median (Q1-Q3)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   | ( ,             |
| Female 2,851 (48.79) Unknown 45 (0.77)  Age, years  18-44 500 (8.56)  45-64 1,469 (25.14)  65-74 1,054 (18.04)  ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (ITO), days Median (Q1-Q3) 1 (1-1)  Drug class Influenza vaccines 61 (1.04)  COVID-19 mRNA vaccines 4,587 (78.50)  Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes  Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)  |   | 2.947 (50.44)   |
| Unknown       45 (0.77)         Age, years       18-44       500 (8.56)         45-64       1,469 (25.14)       65-74         65-74       1,054 (18.04)       ≥75         Unknown       1,388 (23.75)       1,432 (24.51)         Unknown       1,388 (23.75)       Delay (TTO), days         Median (Ω1-Q3)       1 (1-1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   |                 |
| Age, years  18–44  45–64  45–64  65–74  1,054 (18.04)  ≥75  1,432 (24.51)  Unknown  1,388 (23.75)  Delay (TTO), days  Median (01–03)  1 (1–1)  Drug class  Influenza vaccines  61 (1.04)  COVID–19 mRNA vaccines  Ad5-vectored COVID–19 vaccines  Inactivated whole-virus COVID–19 vaccines  55 (0.94)  Others*  4,905 (49.72)  Fatal  Unknown  2,694 (46.11)  |   |                 |
| 18-44 500 (8.56) 45-64 1,469 (25.14) 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (TTO), days Median (Q1-Q3) 1 (1-1)  Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)  |   | 13 (0.77)       |
| 45-64 1,469 (25.14) 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (TTO), days Median (Ω1-Q3) 1 (1-1)  Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)   | • ,                                       | EUU (8 EE)      |
| 65-74 1,054 (18.04) ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (TTO), days Median (Q1-Q3) 1 (1-1)  Drug class Influenza vaccines 61 (1.04) COVID-19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID-19 vaccines 1,098 (18.79) Inactivated whole-virus COVID-19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)   |   |                 |
| ≥75 1,432 (24.51) Unknown 1,388 (23.75)  Delay (TTO), days Median (Q1–Q3) 1 (1–1)  Drug class Influenza vaccines 61 (1.04) COVID–19 mRNA vaccines 4,587 (78.50) Ad5-vectored COVID–19 vaccines 1,098 (18.79) Inactivated whole-virus COVID–19 vaccines 55 (0.94) Others* 42 (0.72)  Fatal outcomes Alive 2,905 (49.72) Fatal Unknown 2,694 (46.11)   |   |                 |
| Unknown       1,388 (23.75)         Delay (TTO), days         Median (Q1-Q3)       1 (1-1)         Drug class         Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   |                 |
| Delay (TTO), days         Median (Q1–Q3)       1 (1–1)         Drug class         Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes         Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   |                 |
| Median (Q1–Q3)       1 (1–1)         Drug class       Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes         Alive       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   | 1,388 (23.75)   |
| Drug class         Influenza vaccines         61 (1.04)           COVID-19 mRNA vaccines         4,587 (78.50)           Ad5-vectored COVID-19 vaccines         1,098 (18.79)           Inactivated whole-virus COVID-19 vaccines         55 (0.94)           Others*         42 (0.72)           Fatal outcomes         2,905 (49.72)           Fatal         244 (4.18)           Unknown         2,694 (46.11)  |   | . ()            |
| Influenza vaccines       61 (1.04)         COVID-19 mRNA vaccines       4,587 (78.50)         Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   | 1 (1-1)         |
| COVID-19 mRNA vaccines 4,587 (78.50)  Ad5-vectored COVID-19 vaccines 1,098 (18.79)  Inactivated whole-virus COVID-19 vaccines 55 (0.94)  Others* 42 (0.72)  Fatal outcomes  Alive 2,905 (49.72)  Fatal 244 (4.18)  Unknown 2,694 (46.11)   | •   | , ,             |
| Ad5-vectored COVID-19 vaccines       1,098 (18.79)         Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)   |   |                 |
| Inactivated whole-virus COVID-19 vaccines       55 (0.94)         Others*       42 (0.72)         Fatal outcomes       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)  |   |                 |
| Others*       42 (0.72)         Fatal outcomes       2,905 (49.72)         Fatal       244 (4.18)         Unknown       2,694 (46.11)  |   |                 |
| Fatal outcomes  Alive 2,905 (49.72)  Fatal 244 (4.18)  Unknown 2,694 (46.11)   | Inactivated whole-virus COVID-19 vaccines | 55 (0.94)       |
| Alive 2,905 (49.72) Fatal 244 (4.18) Unknown 2,694 (46.11)   | Others*                                   | 42 (0.72)       |
| Fatal 244 (4.18) Unknown 2,694 (46.11)   | Fatal outcomes                            |                 |
| Unknown 2,694 (46.11)  | Alive                                     | 2,905 (49.72)   |
|  | Fatal                                     | 244 (4.18)      |
| Single drug suspected 5,843 (100)  | Unknown                                   | 2,694 (46.11)   |
|  | Single drug suspected                     | 5,843 (100)     |

Values are presented as n (%) unless otherwise indicated. TTO, time to onset.

\*Others: anthrax, brucellosis, cholera, dengue vaccines, diphtheria, Ebola, encephalitis, Haemophilus influenzae type b, hepatitis A, hepatitis B, leptospirosis, measles, meningococcal, mumps, papillomavirus, pertussis, plague, pneumococcal, polio, rabies, rotavirus diarrhea, rubella, smallpox, tetanus toxoids, tuberculosis, typhoid, typhus, varicella zoster and yellow fever vaccines.